Effects of Aspergillus fumigatus colonization on lung function in cystic fibrosis

Current Opinion in Pulmonary Medicine

Volumn 18, Issue 6, 2012, Pages 632-638

  Speirs, Jennifer J ^a   Van Der Ent, Cornelis K ^a   Beekman, Jeffrey M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

allergic bronchopulmonary aspergillosis; Aspergillus fumigatus; colonization; cystic fibrosis; lung function

Indexed keywords

DECTIN 1; ITRACONAZOLE; PLACEBO; TRANSMEMBRANE CONDUCTANCE REGULATOR;

ADAPTIVE IMMUNITY; ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; ANTIBIOTIC THERAPY; ASPERGILLUS FUMIGATUS; BACTERICIDAL ACTIVITY; BODY MASS; BRONCHIECTASIS; COMPUTER ASSISTED TOMOGRAPHY; CYSTIC FIBROSIS; FORCED EXPIRATORY VOLUME; FUNGAL COLONIZATION; FUNGAL STRAIN; FUNGAL VIRULENCE; HIGH THROUGHPUT SEQUENCING; HUMAN; INNATE IMMUNITY; LUNG ASPERGILLOSIS; LUNG CAPACITY; LUNG FUNCTION; LYMPHOCYTE DIFFERENTIATION; MORBIDITY; NONHUMAN; PHAGOCYTOSIS; PSEUDOMONAS AERUGINOSA; PYROSEQUENCING; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSITIZATION; SIGNAL TRANSDUCTION; TH2 CELL;

ASPERGILLUS FUMIGATUS; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; HUMANS; PULMONARY ASPERGILLOSIS; RESPIRATORY FUNCTION TESTS;

EID: 84867033879     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e328358d50b     Document Type: Review

References (44)

1. Charlson ES, Bittinger K, Haas AR, et al. Topographical continuity of bacterial populations in the healthy human respiratory tract. Am J Respir Crit Care Med 2011; 184:957-963.
2. Beck JM, Young VB, Huffnagle GB. The microbiome of the lung. Transl Res 2012. [Epub ahead of print]
3. Pihet M, Carrere J, Cimon B, et al. Occurrence and relevance of filamentous fungi in respiratory secretions of patients with cystic fibrosis-a review. Med Mycol 2009; 47:387-397.
4. Skov M, McKay K, Koch C, Cooper PJ. Prevalence of allergic broncho-pulmonary aspergillosis in cystic fibrosis in an area with a high frequency of atopy. Respir Med 2005; 99:887-893.
5. Leenders AC, van Belkum A, Behrendt M, et al. Density and molecular epidemiology of Aspergillus in air and relationship to outbreaks of Aspergillus infection. J Clin Microbiol 1999; 37:1752-1757.
6. Aimanianda V, Bayry J, Bozza S, et al. Surface hydrophobin prevents immune recognition of airborne fungal spores. Nature 2009; 460:1117-1121.
7. Faro-Trindade I, Willment JA, Kerrigan AM, et al. Characterisation of innate fungal recognition in the lung. PLoS One 2012; 7:e35675.
8. Pier GB. Role of the cystic fibrosis transmembrane conductance regulator in innate immunity to Pseudomonas aeruginosa infections. Proc Natl Acad Sci USA 2000; 97:8822-8828.
9. Pier GB, Grout M, Zaidi TS. Cystic fibrosis transmembrane conductance regulator isan epithelial cell receptor for clearance of Pseudomonas aeruginosa from the lung. Proc Natl Acad Sci USA 1997; 94:12088-12093.
10. Schroeder TH, Lee MM, Yacono PW, et al. CFTR is a pattern recognition molecule that extracts Pseudomonas aeruginosa LPS from the outer membrane into epithelial cells and activates NF-kappa B translocation. Proc Natl Acad Sci USA 2002; 99:6907-6912.
11. Chaudhary N, Datta K, Askin FB, et al. Cystic fibrosis transmembrane conductance regulator regulates epithelial cell response to Aspergillus and resultant pulmonary inflammation. Am JRespir Crit Care Med 2012; 185:301-310.
12. Bruscia EM, Zhang PX, Ferreira E, et al. Macrophages directly contribute to the exaggerated inflammatory response in cystic fibrosis transmembrane conductance regulator-/-mice. Am J Respir Cell Mol Biol 2009; 40:295-304.
13. Di A, Brown ME, Deriy LV, et al. CFTR regulates phagosome acidification in macrophages and alters bactericidal activity. Nat Cell Biol 2006; 8:933-944.
14. Bhatia S, Fei M, Yarlagadda M, et al. Rapid host defense against Aspergillus fumigatus involves alveolar macrophages with a predominance of alternatively activated phenotype. PLoS One 2011; 6:e15943.
15. Mastella G, Rainisio M, Harms HK, et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis. A European epidemiological study. Epidemio-logic Registry of Cystic Fibrosis. Eur Respir J 2000; 16:464-471.
16. Kraemer R, Delosea N, Ballinari P, et al. Effect of allergic bronchopulmonary aspergillosis on lung function in children with cystic fibrosis. Am J Respir Crit Care Med 2006; 174:1211-1220.
17. Stevens DA, Moss RB, Kurup VP, et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis-state of the art: Cystic Fibrosis Foundation Consensus Conference. Clin Infect Dis 2003; 37 (Suppl 3):S225-S264.
18. Warren TA, Yau Y, Ratjen F, et al. Serum galactomannan in cystic fibrosis patients colonized with Aspergillus species. Med Mycol 2012; 50:658-660.
19. Allard JB, Poynter ME, Marr KA, et al. Aspergillus fumigatus generates an enhanced Th2-biased immune response in mice with defective cystic fibrosis transmembrane conductance regulator. J Immunol 2006; 177:5186-5194.
20. Hartl D, Griese M, Kappler M, et al. Pulmonary T(H)2 response in Pseudo-monas aeruginosa-infected patients with cystic fibrosis. J Allergy Clin Immunol 2006; 117:204-211.
21. Chauhan B, Santiago L, Kirschmann DA, et al. The association of HLA-DR alleles and T cell activation with allergic bronchopulmonary aspergillosis. J Immunol 1997; 159:4072-4076.
22. Mueller C, Braag SA, Keeler A, et al. Lack of Cftr in CD3\+ lymphocytes leads to aberrant cytokine secretion and hyper-inflammatory adaptive immune responses. Am J Respir Cell Mol Biol 2010; 44:922-929.
23. de Vrankrijker AM, van der Ent CK, van Berkhout FT, et al. Aspergillus fumigatus colonization in cystic fibrosis: implications for lung function? Clin Microbiol Infect 2011; 17:1381-1386.
24. Amin R, Dupuis A, Aaron SD, Ratjen F. The effect of chronic infection with Aspergillus fumigatus on lung function and hospitalization in patients with cystic fibrosis. Chest 2010; 137:171-176.
25. Fairs A, Agbetile J, Hargadon B, et al. IgE sensitization to Aspergillus fumigatus is associated with reduced lung function in asthma. Am J Respir Crit Care Med 2010; 182:1362-1368.
26. Lebecque P, Pepermans X, Marchand E, et al. ABPA in adulthood: a CFTR-related disorder. Thorax 2010; 66:540-541.
27. Miller PW, Hamosh A, Macek M Jr, et al. Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations in allergic bronchopulmonary aspergillosis. Am J Hum Genet 1996; 59:45-51.
28. McMahon MA, Chotirmall SH, McCullagh B, et al. Radiological abnormalities associated with Aspergillus colonization in a cystic fibrosis population. Eur J Radiol 2012; 81:e197-202.
29. Aaron SD, Vandemheen KL, Freitag A, et al. Treatment of Aspergillus fumigatus in patients with cystic fibrosis: a randomized, placebo-controlled pilot study. PLoS One 2012; 7:e36077.
30. Wark PA, Gibson PG, Wilson AJ. Azoles for allergic bronchopulmonary aspergillosis associated with asthma. Cochrane Database Syst Rev 2004:CD001108.
31. Pasqualotto AC, Powell G, Niven R, Denning DW. The effects of antifungal therapy on severe asthma with fungal sensitization and allergic bronchopulmonary aspergillosis. Respirology 2009; 14:1121-1127.
32. Stevens DA, Schwartz HJ, Lee JY, et al. A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis. N Engl J Med 2000; 342:756-762.
33. Chishimba L, Niven RM, Cooley J, Denning DW. Voriconazole and posacona-zole improve asthma severity in allergic bronchopulmonary aspergillosis and severe asthma with fungal sensitization. J Asthma 2012; 49:423-433.
34. Burgel PR, Baixench MT, Amsellem M, et al. High prevalence of azole-resistant Aspergillus fumigatus in adults with cystic fibrosis exposed to itraconazole. Antimicrob Agents Chemother 2012; 56:869-874.
35. van der Linden JW, Snelders E, Kampinga GA, et al. Clinical implications of azole resistance in Aspergillus fumigatus, The Netherlands, 2007-2009. Emerg Infect Dis 2011; 17:1846-1854.
36. Morio F, Aubin GG, Danner-Boucher I, et al. High prevalence of triazole resistance in Aspergillus fumigatus, especially mediated by TR/L98H, in a French cohort of patients with cystic fibrosis. J Antimicrob Chemother 2012; 67:1870-1873.
37. Mortensen KL, Jensen RH, Johansen HK, et al. Aspergillus species and other molds in respiratory samples from patients with cystic fibrosis: a laboratory-based study with focus on Aspergillus fumigatus azole resistance. J Clin Microbiol 2011; 49:2243-2251.
38. Delhaes L, Monchy S, Frealle E, et al. The airway microbiota in cystic fibrosis: a complex fungal and bacterial community-implications for therapeutic manage ment. PLoS One 2012; 7:e36313.
39. Guss AM, Roeselers G, Newton IL, et al. Phylogenetic and metabolic diversity of bacteria associated with cystic fibrosis. ISME J 2011; 5:20-29.
40. Mowat E, Rajendran R, Williams C, et al. Pseudomonas aeruginosa and their small diffusible extracellular molecules inhibit Aspergillus fumigatus biofilm formation. FEMS Microbiol Lett 2010; 313:96-102.
41. van der Ent CK, Hoekstra H, Rijkers GT. Successful treatment of allergic bronchopulmonary aspergillosis with recombinant anti-IgE antibody. Thorax 2007; 62:276-277.
42. Kanu A, Patel K. Treatment of allergic bronchopulmonary aspergillosis (ABPA) in CF with anti-IgE antibody (omalizumab). Pediatr Pulmonol 2008; 43:1249-1251.
43. Lebecque P, Leonard A, Argaz M, et al. Omalizumab for exacerbations of allergic bronchopulmonary aspergillosis in patients with cystic fibrosis. BMJ Case Rep 2009; 2009. doi: bcr07.2008.0379.
44. Zirbes JM, Milla CE. Steroid-sparing effect of omalizumab for allergic broncho-pulmonary aspergillosis and cystic fibrosis. Pediatr Pulmonol 2008; 43:607-610.